Credit Suisse’s Artelo Biosciences ARTL Stock Holding History

Credit Suisse’s Portfolio ARTL Stock Details ARTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-44	Closed	-$9K	–	4284
2020 Q4	$9K	Buy	+44	New	+$7.57K	﹤0.01%	4314

Other funds holding ARTL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

LCM

LVM Capital Management Portage, Michigan $1.19B AUM 41.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Credit Suisse's ARTL Position: Q1 2021 in Review

Credit Suisse sold out of Artelo Biosciences (ARTL) in Q1 2021, closing a stake of 44 shares — an estimated $9K sold.

Credit Suisse first reported a position in ARTL in Q4 2020 and held it in 1 quarter. The position peaked at $9K in Q4 2020. 13 funds tracked by Wall St. Rank hold ARTL as of Q1 2021.

Credit Suisse reported no remaining Artelo Biosciences position as of Q1 2021 after selling out during the quarter.
Credit Suisse sold 44 Artelo Biosciences shares in Q1 2021, an estimated $9K.
Credit Suisse first reported a position in Artelo Biosciences in Q4 2020 and held it in 1 quarter.
Credit Suisse's Artelo Biosciences position peaked at $9K in Q4 2020.
13 funds tracked by Wall St. Rank held Artelo Biosciences as of Q1 2021.

Based on Credit Suisse's 13F filing for Q1 2021, filed 14 May 2021.